"The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea an"...
Ontak Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Ontak (denileukin diftitox) is used to treat leukemia and lymphomas, including cutaneous (of the skin) T-cell lymphoma. It works by killing certain blood/cancer cells from the immune system (e.g., B cells, T cells). Common side effects include dizziness, back pain, mild rash/itching, flushing, fever, chills, muscle/joint pain, nausea, vomiting, or diarrhea during or after the infusion.
The dose of Ontak is 9 or 18 mcg/kg/day administered by intravenous infusion over 30-60 minutes for 5 consecutive days every 21 days for 8 cycles. Patients should be premedicated with an antihistamine and acetaminophen prior to each infusion. Other drugs may interact with Ontak. Tell your doctor all medications and supplements you use. During pregnancy, Ontak should be used only when prescribed. It is unknown if this drug passes into breast milk and the effect on a nursing infant is unknown. Consult your doctor before breastfeeding.
Our Ontak (denileukin diftitox) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Ontak in Detail - Patient Information: Side Effects
You may have a reaction from a denileukin diftitox injection within hours or days after receiving the injection. Call your doctor promptly if you have one or more of these symptoms: fever, chills, weakness, muscle or joint pain, nausea, vomiting, or stomach upset.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
- blurred vision, changes in color vision;
- swelling in your hands, ankles, or feet;
- easy bruising or bleeding, unusual weakness;
- fever, chills, body aches, cough, flu symptoms;
- fast heart rate;
- feeling light-headed, fainting;
- back pain, trouble breathing, chest pain or tightness;
- trouble swallowing, tight feeling in your throat; or
- warmth or redness in your face, neck, or chest.
Less serious side effects may include:
- headache, dizziness, or nervousness;
- numbness or tingling;
- runny or stuffy nose;
- skin itching or rash;
- weight gain or loss;
- mild diarrhea or constipation; or
- nausea, vomiting, loss of appetite.
Read the entire detailed patient monograph for Ontak (Denileukin Diftitox)
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Ontak Overview - Patient Information: Side Effects
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Ontak (Denileukin Diftitox)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Ontak FDA Prescribing Information: Side Effects
The following adverse reactions are discussed in greater detail in other sections of the label:
- Infusion Reactions [seeWARNINGS AND PRECAUTIONS ]
- Capillary Leak Syndrome [see WARNINGS AND PRECAUTIONS]
- Visual Loss [see WARNINGS AND PRECAUTIONS]
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Safety data are available for 3 clinical studies in which 234 patients received Ontak (denileukin diftitox) at 9 mcg/kg (n=80) or 18 mcg/kg (n=154) at the recommended schedule. Of these studies, 1 was placebo-controlled and dose-ranging (Study 1, 100 Ontak (denileukin diftitox) -treated patients), one was a dose-comparison of 9 and 18 mcg/kg (Study 2, n=71), and the third was a single-arm study using 18 mcg/kg (n=63); all studies were limited to adult patients with CTCL. The median age of patients across the clinical studies was 60 years (range 23-91 years) and 36% (n=85) were 65 years of age or older; 55% were men and 85% were Caucasian.
Across all 3 studies, the most common adverse reactions in Ontak (denileukin diftitox) -treated patients ( ≥ 20%) were pyrexia, nausea, fatigue, rigors, vomiting, diarrhea, headache, peripheral edema, cough, dyspnea and pruritus. The most common serious adverse reactions were capillary leak syndrome (11.1%), infusion reactions (8.1%), and visual changes including loss of visual acuity (4%). Ontak (denileukin diftitox) was discontinued in 28.2% (66/234) of patients due to adverse reactions.
The data described in Table 1 reflect exposure to Ontak (denileukin diftitox) in 100 patients administered as a single agent at the recommended dosing schedule in the randomized placebo-controlled trial (Study 1). The median number of Ontak (denileukin diftitox) cycles was 7 (range 1-10) for the 9 mcg/kg cohort and 6 (range 1-11) for the 18 mcg/kg cohort. The median age of patients was 59 years (range 23-84 years) and 34% (n=34) were 65 years of age or older; 55% were men and 86% were Caucasian.
Table 1: Incidence of Adverse Reactions Occurring in ≥ 10%
of Ontak (denileukin diftitox) -treated patients (18 mcg/kg group) and at a higher rate than Placebo
in Study 1
|Ontak (denileukin diftitox)
|Ontak (denileukin diftitox)
|Pyrexia||7 (15.9)||22 (48.9)||35 (63.6)|
|Nausea||10 (22.7)||21 (46.7)||33 (60.0)|
|Rigors||9 (20.5)||19 (42.2)||26 (47.3)|
|Fatigue||14 (31.8)||21 (46.7)||24 (43.6)|
|Vomiting||3 (6.8)||6 (13.3)||19 (34.5)|
|Headache||8 (18.2)||13 (28.9)||14 (25.5)|
|Edema peripheral||10 (22.7)||9 (20.0)||14 (25.5)|
|Diarrhea||4 (9.1)||10 (22.2)||12 (21.8)|
|Anorexia||2 (4.5)||4 (8.9)||11 (20.0)|
|Rash||2 (4.5)||11 (24.4)||11 (20.0)|
|Myalgia||2 (4.5)||8 (17.8)||11 (20.0)|
|Cough||3 (6.8)||9 (20.0)||10 (18.2)|
|Pruritus||4 (9.1)||7 (15.6)||10 (18.2)|
|Back pain||1 (2.3)||7 (15.6)||10 (18.2)|
|Asthenia||2 (4.5)||8 (17.8)||10 (18.2)|
|Hypotension||1 (2.3)||3 (6.7)||9 (16.4)|
|Upper respiratory tract infection||5 (11.4)||6 (13.3)||7 (12.7)|
|Dizziness||5 (11.4)||5 (11.1)||7 (12.7)|
|Arthralgia||5 (11.4)||7 (15.6)||7 (12.7)|
|Pain||3 (6.8)||5 (11.1)||7 (12.7)|
|Chest pain||1 (2.3)||2 (4.4)||7 (12.7)|
|Dysgeusia||1 (2.3)||0 (0)||6 (10.9)|
|Dyspnea||2 (4.5)||6 (13.3)||6 (10.9)|
Hepatobiliary Disorders: Increase in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) from baseline occurred in 84% of subjects treated with Ontak (denileukin diftitox) (197/234). In the majority of subjects, these enzyme elevations occurred during either the first or the second cycle; enzyme elevation resolved without medical intervention and did not require discontinuation of Ontak (denileukin diftitox) .
An immune response to denileukin diftitox was assessed using 2 enzyme-linked immunoassays (ELISA). The first assay measured reactivity directed against intact denileukin diftitox calibrated against anti-diphtheria toxin, and the second assay measured reactivity against the IL-2 portion of the protein. An additional in vitro cell-based assay that measured the ability of antibodies in serum to protect a human IL-2R-expressing cell line from toxicity by denileukin diftitox, was used to detect the presence of neutralizing antibodies which inhibited functional activity. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to the intact fusion protein denileukin diftitox. These results are highly dependent on the sensitivity and the specificity of the assays. Additionally, the observed incidence of the antibody positivity may be influenced by several factors, including sample handling, concomitant medication, and underlying disease. For these reasons, the comparison of the incidence of antibodies to denileukin diftitox with the incidence of antibodies to other products may be misleading.
In Study 1 [see Clinical Studies], of 95 patients treated with denileukin diftitox, 66% tested positive for antibodies at baseline probably due to a prior exposure to diphtheria toxin or its vaccine. After 1, 2, and 3 courses of treatment, 94%, 99%, and 100% of patients tested positive, respectively. Mean titers of anti-denileukin diftitox antibodies were similarly increased in the 9 and 18 mcg/kg/day dose groups after 2 courses of treatment. Meanwhile, pharmacokinetic parameters decreased substantially (Cmax~57%, AUC~80%), and clearance increased 2- to 8- fold.
In Study 2 [see Clinical Studies], 131 patients were assessed for binding antibodies. Of these, 51 patients (39%) had antibodies at baseline. Seventy-six percent of patients tested positive after 1 course of treatment and 97% after 3 courses of treatment. Neutralizing antibodies were assessed in 60 patients; 45%, 73%, and 97% had evidence of inhibited functional activity in the cellular assay at baseline and after 1 and 3 courses of treatment, respectively.
Read the entire FDA prescribing information for Ontak (Denileukin Diftitox)
Additional Ontak Information
Ontak - User Reviews
Ontak User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.